iBio (IBIO) Change in Account Payables (2010 - 2026)
iBio (IBIO) posted quarterly Change in Account Payables of $380000.0 for Q1 2026, down 55.97% year-over-year from $863000.0 in Q1 2025, and up 1410.34% quarter-over-quarter from -$29000.0 in Q4 2025.
iBio (IBIO) Change in Account Payables (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Change in Account Payables for 17 consecutive years, with $380000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 55.97% year-over-year to $380000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 525.7% YoY), while the FY2025 annual figure was $1.8 million, up 222.8% from the prior year.
- Change in Account Payables improved to $380000.0 in Q1 2026 per IBIO's latest filing, from -$29000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.0 million in Q4 2022 and bottomed at -$1.7 million in Q1 2023.
- Historically, Change in Account Payables has averaged $54588.2 across 5 years, with a median of $62000.0 in 2023.
- On a YoY basis, Change in Account Payables climbed as much as 701.61% in 2024 and fell as far as 504.17% in 2024.
- iBio's Change in Account Payables stood at $1.0 million in 2022, then plunged by 105.04% to -$51000.0 in 2023, then sank by 372.55% to -$241000.0 in 2024, then surged by 87.97% to -$29000.0 in 2025, then surged by 1410.34% to $380000.0 in 2026.
- Business Quant data shows IBIO's Change in Account Payables at $380000.0 in Q1 2026, -$29000.0 in Q4 2025, and $495000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 380,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 380,000.00 |
| Mar 31, 2026 | 380,000.00 |
| Dec 31, 2025 | -29,000.00 |
| Dec 31, 2025 | -29,000.00 |
| Sep 30, 2025 | 495,000.00 |
| Sep 30, 2025 | 495,000.00 |
| Jun 30, 2025 | 712,000.00 |
| Jun 30, 2025 | 712,000.00 |
| Mar 31, 2025 | 863,000.00 |
| Mar 31, 2025 | 863,000.00 |
| Dec 31, 2024 | -241,000.00 |
| Dec 31, 2024 | -241,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Jun 30, 2024 | -870,000.00 |
| Jun 30, 2024 | -870,000.00 |
| Mar 31, 2024 | -632,000.00 |
| Mar 31, 2024 | -632,000.00 |
| Dec 31, 2023 | -51,000.00 |
| Dec 31, 2023 | -51,000.00 |